Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE